DIVI'S LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,016 INR | +4.49% |
|
+9.39% | +2.88% |
| Apr. 26 | Weak March Quarter Earnings Weigh Down Indian Equities on Friday | MT |
| Apr. 25 | Divi's Laboratories Plans Up To INR7 Billion Investment to Boost Capacity | MT |
ETFs positioned on Divi's Laboratories Limited
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.68% | 6 M€ | +6.07% | - | |
| 0.20% | 11 M€ | +1.79% | ||
| 0.09% | 18 M€ | +3.66% | ||
| 0.08% | 2,808 M€ | +5.90% | - | |
| 0.08% | 441 M€ | +4.60% | - | |
| 0.08% | 149 M€ | +2.17% | - | |
| 0.07% | 4 M€ | -4.41% | - | |
| 0.06% | 117 M€ | +1.11% | - | |
| 0.03% | 31 M€ | +3.50% | - | |
| 0.03% | 7 M€ | +1.95% | - | |
| 0.02% | 7 M€ | +26.90% | - | |
| 0.01% | 15 M€ | +11.24% | ||
| 0.01% | 34 M€ | +2.14% | - | |
| 0.01% | 34 M€ | +6.71% | - | |
| 0.01% | 389 M€ | +6.83% | - | |
| 0.01% | 16 M€ | -8.49% | ||
| 0.00% | 147 M€ | +4.88% | - | |
| 0.00% | 39 M€ | +3.67% | - | |
| 0.00% | 302 M€ | +3.80% | - |
Divi's Laboratories Limited is specialized in the development and manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients.
Net sales by source of revenue break down into product sales (97.9%) and service sales (2.1%).
At the end of March 2020, the group has 2 production sites located in India.
Sector
Pharmaceuticals
Calendar
2024-05-26
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
25
Last Close Price
4,016
INR
Average target price
3,442
INR
Spread / Average Target
-14.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.88% | 12.78B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- DIVISLAB Stock
- Funds and ETFs Divi's Laboratories Limited
